SCHEMBL2296725

SCHEMBL2296725

CC(O)CON1C(=O)c2ccccc2C1=O

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GAA P10253 1/20 0.53
ALDH1A1 P00352 5/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 1/20 0.50
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
HPGD P15428 1/20 0.47
ATM Q13315 1/20 0.47
MAPT P10636 1/20 0.46
RECQL P46063 1/20 0.45
HTT P42858 1/20 0.43
LMNA P02545 1/20 0.43
PLA2G1B P04054 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31208299 1.00 POLB (0.58) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL2296722 1.00 POLB (0.58) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL8752996 0.86 POLB (0.56) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL19961833 0.85 GAA (0.56) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL3576904 0.85 GAA (0.56) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL529416 0.85 POLB (0.70) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL26316343 0.82 GAA (0.53) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL3978571 0.81 POLB (0.55) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL21501547 0.81 GAA (0.51) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL6526529 0.81 POLB (0.61) POLBSMN1; SMN2GAAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409533-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-12-12 US disclosed
US-12071433-B2 HMOX1 inducers Astellas Engineered Small Molecules US, Incorporated (US) 2024-08-27 US disclosed
US-20240051952-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-02-15 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
EP-3952990-A1 HMOX1 INDUCERS Mitobridge, Inc. (US) 2022-02-16 EP disclosed
CN-113874074-A HMOX1 inducers 米托布里奇公司 2021-12-31 CN disclosed
WO-2020210339-A1 HMOX1 INDUCERS MITOBRIDGE, INC. (US) 2020-10-15 WO disclosed
WO-2020210339-A1 HMOX1 INDUCERS MITOBRIDGE, INC. (US) 2020-10-15 WO disclosed
US-10766888-B1 HMOX1 inducers MITOBRIDGE INC. (US) 2020-09-08 US disclosed
US-10766888-B1 HMOX1 inducers MITOBRIDGE INC. (US) 2020-09-08 US disclosed
US-8841462-B2 Bicyclic heterocycles as MEK kinase inhibitors GENENTECH, INC. 2014-09-23 US disclosed
US-20110190257-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS GENETECH, INC. (US) 2011-08-04 US disclosed
US-20110190257-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS GENETECH, INC. (US) 2011-08-04 US disclosed
US-20110190257-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS GENETECH, INC. (US) 2011-08-04 US disclosed
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190257-A1 BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS MAP2K7, MAP3K1, MAP3K5 POLB 835/4885SMN1; SMN2 3917/4885GAA 4093/4885
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 POLB 2626/4885SMN1; SMN2 3776/4885GAA 1717/4885
US-10766888-B1 HMOX1 inducers HMOX1, HMOX2, HMBS POLB 3184/4885SMN1; SMN2 2893/4885GAA 2202/4885
US-20240409533-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS POLB 3184/4885SMN1; SMN2 2893/4885GAA 2202/4885
US-12071433-B2 HMOX1 inducers HMOX1, HMOX2, HMBS POLB 2840/4885SMN1; SMN2 2872/4885GAA 2123/4885
US-20240051952-A1 HMOX1 INDUCERS HMOX1, HMOX2, QSOX1 POLB 3833/4885SMN1; SMN2 3190/4885GAA 1965/4885
US-20220177460-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS POLB 2840/4885SMN1; SMN2 2872/4885GAA 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.